Raymond James Downgrades Acadia Pharmaceuticals (ACAD) to Market Perform, After Receiving CRL From FDA

April 5, 2021 3:08 PM EDT
Get Alerts ACAD Hot Sheet
Price: $20.60 +0.83%

Rating Summary:
    10 Buy, 13 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 12 | Down: 16 | New: 51
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Raymond James analyst Danielle Brill downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $25.59 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Raymond James, FDA